

Leendert A Trouw

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/89143/publications.pdf>

Version: 2024-02-01

219
papers

9,826
citations

30070

54
h-index

43889

91
g-index

255
all docs

255
docs citations

255
times ranked

9423
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-carbamylated protein antibodies positivity and disease activity in Hispanic patients with established rheumatoid arthritis: An observational study. <i>Modern Rheumatology</i> , 2022, 32, 330-337.	1.8	0
2	Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells. <i>European Journal of Immunology</i> , 2022, , .	2.9	5
3	B-cell activating factor and IL-21 levels predict treatment response in autoimmune hepatitis. <i>JHEP Reports</i> , 2022, 4, 100460.	4.9	5
4	Autoantibodies against specific post-translationally modified proteins are present in patients with lupus and associate with major neuropsychiatric manifestations. <i>RMD Open</i> , 2022, 8, e002079.	3.8	9
5	Arthritis autoantibodies in individuals without rheumatoid arthritis: follow-up data from a Dutch population-based cohort (Lifelines). <i>Rheumatology</i> , 2021, 60, 658-666.	1.9	7
6	Autoantibodies are major predictors of arthritis development in patients with anti-citrullinated protein antibodies and musculoskeletal pain. <i>Scandinavian Journal of Rheumatology</i> , 2021, 50, 189-197.	1.1	12
7	<i><i>HLAâ€“B*08</i></i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Antiâ€“Carbamylated Protein Antibodyâ€“Positive/Antiâ€“Cyclic Citrullinated Peptideâ€“Negative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 963-969.	5.6	12
8	AB0113â€“...ANTI-CARBAMYLATED PROTEIN ANTIBODIES POSITIVITY AND DISEASE ACTIVITY IN HISPANIC PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1085-1086.	0.9	0
9	Placental Complement Activation in Fetal and Neonatal Alloimmune Thrombocytopenia: An Observational Study. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6763.	4.1	7
10	Antiâ€“C1q autoantibodies may not serve as an adequate biomarker for lung manifestations in systemic sclerosis: a singleâ€“centre, crossâ€“sectional study. <i>British Journal of Dermatology</i> , 2021, 185, 657-658.	1.5	0
11	Auto-antibodies to post-translationally modified proteins in osteoarthritis. <i>Osteoarthritis and Cartilage</i> , 2021, 29, 924-933.	1.3	14
12	Cross-reactivity of IgM anti-modified protein antibodies in rheumatoid arthritis despite limited mutational load. <i>Arthritis Research and Therapy</i> , 2021, 23, 230.	3.5	12
13	Circulating C1q levels in health and disease, more than just a biomarker. <i>Molecular Immunology</i> , 2021, 140, 206-216.	2.2	22
14	Anti-carbamylated protein antibodies: are they useful for the diagnosis of rheumatoid arthritis?. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 146-150.	0.8	0
15	Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 570-577.	0.8	5
16	Mass-spectrometric identification of carbamylated proteins present in the joints of rheumatoid arthritis patients and controls. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 570-577.	0.8	10
17	Complement component C1q is produced by isolated articular chondrocytes. <i>Osteoarthritis and Cartilage</i> , 2020, 28, 675-684.	1.3	16
18	Carbamylation reduces the capacity of IgG for hexamerization and complement activation. <i>Clinical and Experimental Immunology</i> , 2020, 200, 1-11.	2.6	9

#	ARTICLE	IF	CITATIONS
19	Long-term follow-up of patients with anti-cyclic citrullinated peptide antibody-positive connective tissue disease: a retrospective observational study including information on the HLA-DRB1 allele and citrullination dependency. <i>Arthritis Research and Therapy</i> , 2020, 22, 248.	3.5	2
20	Inverse correlation between serum complement component C1q levels and whole blood type 1 interferon signature in active tuberculosis and QuantiFERON-positive uveitis: implications for diagnosis. <i>Clinical and Translational Immunology</i> , 2020, 9, e1196.	3.8	5
21	Expression and production of the SERPING1-encoded endogenous complement regulator C1-inhibitor in multiple cohorts of tuberculosis patients. <i>Molecular Immunology</i> , 2020, 120, 187-195.	2.2	19
22	The role of complement activation in autoimmune liver disease. <i>Autoimmunity Reviews</i> , 2020, 19, 102534.	5.8	15
23	Systemic and pulmonary C1q as biomarker of progressive disease in experimental non-human primate tuberculosis. <i>Scientific Reports</i> , 2020, 10, 6290.	3.3	11
24	Substitution of the quantitative serological component in the 2010 criteria for RA with qualitative presence of three autoantibodies yields similar performance: response to the article by Regueiro et al.. <i>Arthritis Research and Therapy</i> , 2020, 22, 85.	3.5	4
25	SAT0585...GEO-EPIDEMIOLOGY OF AUTOANTIBODIES IN RA: DIFFERENT PREVALENCES IN FOUR ETHNICALLY DIVERSE RA POPULATIONS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1251.1-1252.	0.9	5
26	Secretory form of rheumatoid arthritis-associated autoantibodies in serum are mainly of the IgM isotype, suggesting a continuous reactivation of autoantibody responses at mucosal surfaces. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 146-148.	0.9	22
27	Complex medical history of a patient with a compound heterozygous mutation in C1QC. <i>Lupus</i> , 2019, 28, 1255-1260.	1.6	3
28	Complement activation and regulation in rheumatic disease. <i>Seminars in Immunology</i> , 2019, 45, 101339.	5.6	20
29	In rheumatoid arthritis, changes in autoantibody levels reflect intensity of immunosuppression, not subsequent treatment response. <i>Arthritis Research and Therapy</i> , 2019, 21, 28.	3.5	33
30	Different classes of anti-modified protein antibodies are induced on exposure to antigens expressing only one type of modification. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 908-916.	0.9	34
31	Glomerular C4d deposition can precede the development of focal segmental glomerulosclerosis. <i>Kidney International</i> , 2019, 96, 738-749.	5.2	14
32	Screening for two or three autoantibodies in persons at risk for RA: implications of current data for clinical practice. <i>Rheumatology</i> , 2019, 58, 914-915.	1.9	2
33	Presence of Autoantibodies in Erosive Hand Osteoarthritis and Association with Clinical Presentation. <i>Journal of Rheumatology</i> , 2019, 46, 101-105.	2.0	14
34	The role of complement in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Current Opinion in Rheumatology</i> , 2019, 31, 3-8.	4.3	6
35	P026...Baseline autoantibody profile in rheumatoid arthritis associates with early treatment response but not long-term outcomes. , 2018, , .		0
36	Pitfalls in the detection of citrullination and carbamylation. <i>Autoimmunity Reviews</i> , 2018, 17, 136-141.	5.8	34

#	ARTICLE	IF	CITATIONS
37	P007â€¦.In ra, becoming seronegative over the 1st year of dmard treatment does not translate to better chances of drug-free remission in the long-term. , 2018, , .		0
38	Baseline autoantibody profile in rheumatoid arthritisÂs associated with early treatment response but not long-term outcomes. Arthritis Research and Therapy, 2018, 20, 33.	3.5	39
39	The extensive glycosylation of the ACPA variable domain observed for ACPA-IgG is absent from ACPA-IgM. Annals of the Rheumatic Diseases, 2018, 77, 1087-1088.	0.9	14
40	Complement Activation in Patients With Diabetic Nephropathy. Kidney International Reports, 2018, 3, 302-313.	0.8	37
41	SAT0579â€¦.Presence of autoantibodies in erosive hand osteoarthritis and association with clinical presentation. , 2018, , .		0
42	Age and Sex-Associated Changes of Complement Activity and Complement Levels in a Healthy Caucasian Population. Frontiers in Immunology, 2018, 9, 2664.	4.8	165
43	Complement Component C1q as Serum Biomarker to Detect Active Tuberculosis. Frontiers in Immunology, 2018, 9, 2427.	4.8	43
44	Complement component C1q as serum biomarker to detect active tuberculosis. Molecular Immunology, 2018, 102, 185.	2.2	1
45	Triple Positivity for Antiâ€œCitruLLinated Protein Autoantibodies, Rheumatoid Factor, and Antiâ€œCarbamylated Protein Antibodies Conferring High Specificity for Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1721-1731.	5.6	81
46	The anti-carbamylated protein antibody response is of overall low avidity despite extensive isotype switching. Rheumatology, 2018, 57, 1583-1591.	1.9	11
47	Antiâ€œCarbamylated Protein Antibodies and Higher Baseline Disease Activity in Rheumatoid Arthritisâ€œA Replication Study in Three Cohorts: Comment on the Article by Truchetet et al. Arthritis and Rheumatology, 2018, 70, 2096-2097.	5.6	6
48	In RA, becoming seronegative over the first year of treatment does not translate to better chances of drug-free remission. Annals of the Rheumatic Diseases, 2018, 77, 1836-1838.	0.9	12
49	Does information on novel identified autoantibodies contribute to predicting the progression from undifferentiated arthritis to rheumatoid arthritis: a study on anti-CarP antibodies as an example. Arthritis Research and Therapy, 2018, 20, 94.	3.5	9
50	THU0069â€¦.In ra, becoming seronegative over the 1st year of dmard treatment does not translate to better chances of sustained drug-free remission in the long-term. , 2018, , .		0
51	The association between anti-carbamylated protein (anti-CarP) antibodies and radiographic progression in early rheumatoid arthritis: a study exploring replication and the added value to ACPA and rheumatoid factor. Annals of the Rheumatic Diseases, 2017, 76, 112-118.	0.9	67
52	Rheumatoid arthritis phenotype at presentation differs depending on the number of autoantibodies present. Annals of the Rheumatic Diseases, 2017, 76, 716-720.	0.9	35
53	Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nature Reviews Rheumatology, 2017, 13, 331-339.	8.0	109
54	Identification of Lifelines participants at high risk for development of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2017, 76, e43-e43.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Production of complement components by cells of the immune system. <i>Clinical and Experimental Immunology</i> , 2017, 188, 183-194.	2.6	350
56	Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1184-1190.	0.9	73
57	C1q-Dependent Dendritic Cell Cross-Presentation of In Vivo Formed Antigen-Antibody Complexes. <i>Journal of Immunology</i> , 2017, 198, 4235-4243.	0.8	21
58	Breach of autoreactive B cell tolerance by post-translationally modified proteins. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1449-1457.	0.9	27
59	The prevalence of ACPA is lower in rheumatoid arthritis patients with an older age of onset but the composition of the ACPA response appears identical. <i>Arthritis Research and Therapy</i> , 2017, 19, 115.	3.5	23
60	Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2017, 80, 77-84.	6.5	34
61	Excretions/secretions from medicinal larvae (<i>Lucilia sericata</i>) inhibit complement activation by two mechanisms. <i>Wound Repair and Regeneration</i> , 2017, 25, 41-50.	3.0	22
62	The risk of individual autoantibodies, autoantibody combinations and levels for arthritis development in clinically suspect arthralgia. <i>Rheumatology</i> , 2017, 56, 2145-2153.	1.9	50
63	Short article. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 345-348.	1.6	6
64	The complement system as a potential therapeutic target in rheumatic disease. <i>Nature Reviews Rheumatology</i> , 2017, 13, 538-547.	8.0	147
65	Anti-citrullinated protein antibodies in the diagnosis of rheumatoid arthritis (RA): diagnostic performance of automated anti-CCP-2 and anti-CCP-3 antibodies assays. <i>Clinical Rheumatology</i> , 2017, 36, 1487-1492.	2.2	27
66	08.26 The prevalence of acpa is lower in rheumatoid arthritis patients with a higher age of onset but the composition of the acpa response appears identical. , 2017, , .		0
67	THU0068 The risk of individual autoantibodies, autoantibody combinations and autoantibody levels for arthritis development in clinically suspect arthralgia. , 2017, , .		0
68	AB0084 Breadth of baseline autoantibody profile and treatment response in rheumatoid arthritis patients. , 2017, , .		0
69	Complement System. , 2017, , 355-365.		0
70	Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production. <i>Frontiers in Immunology</i> , 2017, 8, 285.	4.8	57
71	The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2017, 19, 190.	3.5	20
72	Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 246.	3.5	15

#	ARTICLE	IF	CITATIONS
73	C1q Deficiency and Neuropsychiatric Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2016, 7, 647.	4.8	30
74	AB0086â€¦Anti-Citrullinated Protein Antibodies in Patients with Cardiovascular Disease without RA. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 926.1-926.	0.9	0
75	A2.05â€¦Carbamylated autoantigens facilitate the break of tolerance: A novel mechanism in the pathogenesis of autoimmune arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A17.1-A17.	0.9	0
76	Smoking is associated with the concurrent presence of multiple autoantibodies in rheumatoid arthritis rather than with anti-citrullinated protein antibodies per se: a multicenter cohort study. <i>Arthritis Research and Therapy</i> , 2016, 18, 285.	3.5	43
77	Anti-carbamylated protein antibodies: a specific hallmark for rheumatoid arthritis. Comparison to conditions known for enhanced carbamylation; renal failure, smoking and chronic inflammation. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1575-1576.	0.9	32
78	A2.10â€¦The isotype and subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A19.1-A19.	0.9	0
79	Predictive factors of radiological progression after 2â€¦years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED study. <i>RMD Open</i> , 2016, 2, e000172.	3.8	13
80	MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. <i>Arthritis Research and Therapy</i> , 2016, 18, 179.	3.5	17
81	Antibodies against carbamylated proteins and cyclic citrullinated peptides in systemic lupus erythematosus: results from two well-defined European cohorts. <i>Arthritis Research and Therapy</i> , 2016, 18, 289.	3.5	43
82	The production and secretion of complement component C1q by human mast cells. <i>Molecular Immunology</i> , 2016, 78, 164-170.	2.2	34
83	Reply. <i>Arthritis and Rheumatology</i> , 2016, 68, 2826-2827.	5.6	1
84	Role of Antiâ€¦Carbamylated Protein Antibodies Compared to Antiâ€¦Citrullinated Protein Antibodies in Indigenous North Americans With Rheumatoid Arthritis, Their Firstâ€¦Degree Relatives, and Healthy Controls. <i>Arthritis and Rheumatology</i> , 2016, 68, 2090-2098.	5.6	36
85	Autoantibody testing to predict response to therapy in RA. <i>Nature Reviews Rheumatology</i> , 2016, 12, 566-568.	8.0	8
86	Excretions/secretions from medicinal larvae (<i>Lucilia sericata</i>) inhibit complement activation by two mechanisms. <i>Immunobiology</i> , 2016, 221, 1137.	1.9	0
87	A5.09â€¦MRI-detected osteitis is not associated with the presence or level of ACPA alone, but with the combined presence of ACPA and RF. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A44.3-A45.	0.9	0
88	A2.15â€¦RA phenotype at presentation differs among patients with few versus many autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A21.1-A21.	0.9	0
89	AB0066â€¦MRI-Detected Osteitis Is Not Associated with The Presence or Level of ACPA Alone, but with The Combined Presence of ACPA and RF. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 919.2-920.	0.9	0
90	Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. <i>Lupus</i> , 2016, 25, 878-888.	1.6	31

#	ARTICLE	IF	CITATIONS
91	Rheumatoid factor isotypes in relation to antibodies against citrullinated peptides and carbamylated proteins before the onset of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 43.	3.5	61
92	Extensive glycosylation of ACPA-IgG variable domains modulates binding to citrullinated antigens in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 578-585.	0.9	161
93	Anticitrullinated protein antibodies and rheumatoid factor are associated with increased mortality but with different causes of death in patients with rheumatoid arthritis: a longitudinal study in three European cohorts. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1924-1932.	0.9	53
94	Anticarbamylated protein antibodies are associated with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1139-1144.	0.9	41
95	FRI0337...anti-C1Q Autoantibodies, C1Q Circulating Immune Complexes and Complement Levels in Patients with Neuropsychiatric Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 556.3-557.	0.9	0
96	THU0114...Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate in the Avert Trial. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 234.3-235.	0.9	4
97	Rheumatoid arthritis-associated autoantibodies in non-rheumatoid arthritis patients with mucosal inflammation: a case-control study. <i>Arthritis Research and Therapy</i> , 2015, 17, 174.	3.5	59
98	The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 339.	3.5	67
99	Anti-citrullinated protein antibodies contribute to platelet activation in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 209.	3.5	63
100	An investigation of the added value of an ACPA multiplex assay in an early rheumatoid arthritis setting. <i>Arthritis Research and Therapy</i> , 2015, 17, 276.	3.5	21
101	Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. <i>Science Translational Medicine</i> , 2015, 7, 290ra87.	12.4	302
102	Complement activation in Glioblastoma Multiforme pathophysiology: Evidence from serum levels and presence of complement activation products in tumor tissue. <i>Journal of Neuroimmunology</i> , 2015, 278, 271-276.	2.3	48
103	C1q, antibodies and anti-C1q autoantibodies. <i>Molecular Immunology</i> , 2015, 68, 6-13.	2.2	53
104	Identification of a novel non-coding mutation in C1qB in a Dutch child with C1q deficiency associated with recurrent infections. <i>Immunobiology</i> , 2015, 220, 422-427.	1.9	15
105	Anti-carbamylated Protein Antibodies Are Present Prior to Rheumatoid Arthritis and Are Associated with Its Future Diagnosis. <i>Journal of Rheumatology</i> , 2015, 42, 572-579.	2.0	107
106	Anti-carbamylated protein antibodies in rheumatoid arthritis patients of Asian descent: Fig. 1. <i>Rheumatology</i> , 2015, 54, 1930-1932.	1.9	25
107	Marked variability in clinical presentation and outcome of patients with C1q immunodeficiency. <i>Journal of Autoimmunity</i> , 2015, 62, 39-44.	6.5	33
108	Anticarbamylated protein antibodies can be detected in animal models of arthritis that require active involvement of the adaptive immune system. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 949-950.	0.9	16

#	ARTICLE	IF	CITATIONS
109	Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. <i>Arthritis Research and Therapy</i> , 2015, 17, 25.	3.5	103
110	Biomarkers for rheumatoid and psoriatic arthritis. <i>Clinical Immunology</i> , 2015, 161, 2-10.	3.2	45
111	A7.4â€¦The specificity of anti-carbamylated protein antibodies for rheumatoid arthritis in a setting of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A76.1-A76.	0.9	0
112	Association of anti-carbamylated protein antibodies with long-term disability and increased disease activity in patients with early inflammatory arthritis: results from the Norfolk Arthritis Register. <i>Lancet, The</i> , 2015, 385, S44.	13.7	10
113	THU0040â€¦In Rheumatoid Arthritis, Smoking is not Associated with Anti-Citrullinated Protein Antibodies (ACPA) Per SE, but with the Concurrent Presence of Rheumatoid Factor, Acpa and Anti-Carbamylated Protein Antibodies. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 206.4-207.	0.9	0
114	Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis. <i>Journal of Rheumatology</i> , 2015, 42, 1786-1793.	2.0	29
115	Anti-citrullinated protein antibodies acquire a pro-inflammatory Fc glycosylation phenotype prior to the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 234-241.	0.9	225
116	A1.45â€¦Hyperglycosylation of ACPA-IGG variable domains modulates reactivity to citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A19.2-A19.	0.9	0
117	FRIO402â€¦Cluster Analysis of an ARRAY of Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus (NPSLE). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 532.3-533.	0.9	0
118	A1.49â€¦Anti-carbamylated protein antibodies (ANTI-CARP) precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A21.1-A21.	0.9	0
119	Five decades of Dutch immunology. <i>Immunology Letters</i> , 2014, 162, 83-84.	2.5	0
120	Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. <i>Autoimmunity Reviews</i> , 2014, 13, 225-230.	5.8	99
121	Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 270-276.	0.9	40
122	Serum autoantibodies directed against transglutaminase-2 have a low avidity compared with alloantibodies against gliadin in coeliac disease. <i>Clinical and Experimental Immunology</i> , 2014, 177, 86-93.	2.6	5
123	Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 780-783.	0.9	185
124	Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1761-1768.	0.9	111
125	A1.28â€¦Anti-carp antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors and smoking. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A11.3-A12.	0.9	1
126	A1.29â€¦In rheumatoid arthritis, smoking is not primarily associated with anti-citrullinated protein antibodies, but with the presence of several autoantibodies. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A12.1-A12.	0.9	0

#	ARTICLE	IF	CITATIONS
127	A1.55â€¦Development of antibodies specific for carbamylated protein precedes disease onset in MICE with collagen-induced arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A23.2-A24.	0.9	1
128	Antibodies Specific for Carbamylated Proteins Precede the Onset of Clinical Symptoms in Mice with Collagen Induced Arthritis. <i>PLoS ONE</i> , 2014, 9, e102163.	2.5	37
129	Circulating plasmablasts/plasmacells as a source of anticitrullinated protein antibodies in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1259-1263.	0.9	69
130	Recognition of citrullinated and carbamylated proteins by human antibodies: specificity, cross-reactivity and the â€˜AMC-Senshuâ€™ method. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 148-150.	0.9	73
131	Autoimmunity in rheumatoid arthritis: different antigensâ€™ common principles. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, ii132-ii136.	0.9	44
132	Autoantibodies against complement components and functional consequences. <i>Molecular Immunology</i> , 2013, 56, 213-221.	2.2	52
133	Genetic variants in the region of the C1q genes are associated with rheumatoid arthritis. <i>Clinical and Experimental Immunology</i> , 2013, 173, 76-83.	2.6	41
134	The concentration of anticitrullinated protein antibodies in serum and synovial fluid in relation to total immunoglobulin concentrations. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1059-1063.	0.9	21
135	AB0096â€¦Presence of systemic arthritis autoantibodies in non-ra patients with severe periodontitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A814.4-A815.	0.9	1
136	Brief Report: Antiâ€™Carbamylated Protein Antibodies Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 911-915.	6.7	164
137	A5.4â€¦Anti Carbamylated Protein Antibodies (Anti-CarP) Are Present in Arthralgia Patients and Predict the Development of Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A31.2-A31.	0.9	2
138	Anti-C1q Autoantibodies, Novel Tests, and Clinical Consequences. <i>Frontiers in Immunology</i> , 2013, 4, 117.	4.8	55
139	Anticarbamylated protein (anti-CarP) antibodies are present in sera of juvenile idiopathic arthritis (JIA) patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 2053-2055.	0.9	24
140	FR10005â€¦Production of anti-citrullinated protein antibodies by B cell subsets isolated from peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 312.2-312.	0.9	0
141	A5.29â€¦Spontaneous Production of Anti-Citrullinated Protein Antibodies in Cultures of Peripheral Blood Mononuclear Cells and Synovial Fluid Mononuclear Cells Isolated from Patients with Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A41.1-A41.	0.9	0
142	A5.6â€¦Anti-Carbamylated Protein Antibodies are Present in Mice with Collagen induced Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A32.1-A32.	0.9	0
143	A5.14â€¦Homocitrulline-Reactive Antibodies can be Generated from Synovial B-Cells from ACPA-Negative RA Patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A35.1-A35.	0.9	1
144	Novel genetic association of theVTCN1region with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 567-571.	0.9	13

#	ARTICLE	IF	CITATIONS
145	The ACPA recognition profile and subgrouping of ACPA-positive RA patients. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 268-274.	0.9	61
146	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 15-20.	1.8	26
147	Genetic variants of C1q are a risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A54.1-A54.	0.9	0
148	ACPA production by circulating B cells isolated from peripheral blood of patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A33.1-A33.	0.9	2
149	The "Senshu"™ method often used to detect citrullinated proteins does not discriminate between citrullination and carbamylation. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A40.2-A40.	0.9	0
150	The ACPA IgM fine specificity differs from the ACPA IgG antigen-recognition profile. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A33.2-A33.	0.9	0
151	The influence of ACPA status and characteristics on the course of RA. <i>Nature Reviews Rheumatology</i> , 2012, 8, 144-152.	8.0	173
152	Closing the serological gap: promising novel biomarkers for the early diagnosis of rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2012, 12, 318-322.	5.8	124
153	Factor H autoantibodies and deletion of Complement Factor H-Related protein-1 in rheumatic diseases in comparison to atypical hemolytic uremic syndrome. <i>Arthritis Research and Therapy</i> , 2012, 14, R185.	3.5	57
154	Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 1323-1328.	6.7	93
155	Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis. <i>Modern Rheumatology</i> , 2012, 22, 15-20.	1.8	15
156	New biomarkers in rheumatoid arthritis. <i>Netherlands Journal of Medicine</i> , 2012, 70, 392-9.	0.5	30
157	Genetic association and functional consequences of a common SNP in the CD40 region with systemic lupus erythematosus and rheumatoid arthritis in a homogeneous Greek population. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A14-A14.	0.9	1
158	TRAF1/C5, eNOS, C1q, but not STAT4 and PTPN22 gene polymorphisms are associated with genetic susceptibility to systemic lupus erythematosus in Turkey. <i>Human Immunology</i> , 2011, 72, 1210-1213.	2.4	44
159	The major risk alleles of age-related macular degeneration (AMD) in <i>CFH</i> do not play a major role in rheumatoid arthritis (RA). <i>Clinical and Experimental Immunology</i> , 2011, 166, 333-337.	2.6	9
160	Complement activation by (auto-) antibodies. <i>Molecular Immunology</i> , 2011, 48, 1656-1665.	2.2	122
161	The fine specificity of IgM anti-citrullinated protein antibodies (ACPA) is different from that of IgG ACPA. <i>Arthritis Research and Therapy</i> , 2011, 13, R195.	3.5	17
162	The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Arthritis and Rheumatism</i> , 2011, 63, 1823-1832.	6.7	55

#	ARTICLE	IF	CITATIONS
163	Role of complement in innate immunity and host defense. <i>Immunology Letters</i> , 2011, 138, 35-37.	2.5	76
164	The window of opportunity in ACPA-positive rheumatoid arthritis is not explained by ACPA characteristics. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1697-1698.	0.9	6
165	The major risk alleles of age related macular degeneration in CFH, do not play a major role in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A17-A18.	0.9	0
166	Distinct ACPA fine-specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A5-A5.	0.9	0
167	A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2184-2190.	0.9	53
168	Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 188-193.	0.9	118
169	Which elements of the criteria for RA are stable over time?. <i>Rheumatology</i> , 2011, 50, 248-249.	1.9	1
170	Genetic variants of C1q are a risk for rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A17-A17.	0.9	2
171	Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 17372-17377.	7.1	464
172	The interaction between HLA SE alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A1-A1.	0.9	3
173	Low avidity anti-citrullinated protein antibodies (ACPA) are associated with high radiographic progression in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A60-A60.	0.9	0
174	Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1461-1464.	0.9	45
175	Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 373-379.	0.9	69
176	Mutations in complement factor I as found in atypical hemolytic uremic syndrome lead to either altered secretion or altered function of factor I. <i>European Journal of Immunology</i> , 2010, 40, 172-185.	2.9	58
177	C-reactive protein in myocardial infarction binds to circulating microparticles but is not associated with complement activation. <i>Clinical Immunology</i> , 2010, 135, 490-495.	3.2	16
178	Glycan profiling of anti-citrullinated protein antibodies isolated from human serum and synovial fluid. <i>Arthritis and Rheumatism</i> , 2010, 62, 1620-1629.	6.7	183
179	Anti-citrullinated protein antibodies have a low avidity compared to antibodies against recall-antigens. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A7-A7.	0.9	0
180	Anti-CCP antibodies are a collection of ACPA that are cross-reactive to multiple citrullinated antigens. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A8-A8.	0.9	3

#	ARTICLE	IF	CITATIONS
181	Analysis of Binding Sites on Complement Factor I That Are Required for Its Activity. <i>Journal of Biological Chemistry</i> , 2010, 285, 6235-6245.	3.4	28
182	Infiltrating dendritic cells contribute to local synthesis of C1q in murine and human lupus nephritis. <i>Molecular Immunology</i> , 2010, 47, 2129-2137.	2.2	60
183	Both Complement and IgG Fc Receptors Are Required for Development of Attenuated Antiglomerular Basement Membrane Nephritis in Mice. <i>Journal of Immunology</i> , 2009, 183, 3980-3988.	0.8	39
184	Genetic, molecular and functional analyses of complement factor I deficiency. <i>European Journal of Immunology</i> , 2009, 39, 310-323.	2.9	53
185	Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. <i>Arthritis and Rheumatism</i> , 2009, 60, 1923-1931.	6.7	212
186	Complement Inhibitor C4b-Binding Protein in Primary Sjögren's Syndrome and its Association With Other Disease Markers. <i>Scandinavian Journal of Immunology</i> , 2009, 69, 374-380.	2.7	22
187	Complement activation and inhibition: a delicate balance. <i>Trends in Immunology</i> , 2009, 30, 83-90.	6.8	304
188	Role of complement and complement regulators in the removal of apoptotic cells. <i>Molecular Immunology</i> , 2008, 45, 1199-1207.	2.2	164
189	C4b-binding protein in Alzheimer's disease: Binding to A β 42 and to dead cells. <i>Molecular Immunology</i> , 2008, 45, 3649-3660.	2.2	46
190	Complement production and regulation by dendritic cells: Molecular switches between tolerance and immunity. <i>Molecular Immunology</i> , 2008, 45, 4064-4072.	2.2	37
191	Molecular and functional analysis of complement factor I mutations in atypical haemolytic uraemic syndrome patients. <i>Molecular Immunology</i> , 2008, 45, 4131.	2.2	0
192	Properdin binds to late apoptotic and necrotic cells independently of C3b and regulates alternative pathway complement activation. <i>Molecular Immunology</i> , 2008, 45, 4138-4139.	2.2	1
193	Properdin Binds to Late Apoptotic and Necrotic Cells Independently of C3b and Regulates Alternative Pathway Complement Activation. <i>Journal of Immunology</i> , 2008, 180, 7613-7621.	0.8	128
194	C4b-Binding Protein Is Present in Affected Areas of Myocardial Infarction during the Acute Inflammatory Phase and Covers a Larger Area than C3. <i>PLoS ONE</i> , 2008, 3, e2886.	2.5	15
195	C4b-binding Protein and Factor H Compensate for the Loss of Membrane-bound Complement Inhibitors to Protect Apoptotic Cells against Excessive Complement Attack. <i>Journal of Biological Chemistry</i> , 2007, 282, 28540-28548.	3.4	117
196	The Factor H Variant Associated with Age-related Macular Degeneration (His-384) and the Non-disease-associated Form Bind Differentially to C-reactive Protein, Fibromodulin, DNA, and Necrotic Cells. <i>Journal of Biological Chemistry</i> , 2007, 282, 10894-10900.	3.4	126
197	Regulation of complement activation by C-reactive protein: Targeting of the inhibitory activity of C4b-binding protein. <i>Molecular Immunology</i> , 2007, 44, 241.	2.2	1
198	A mutation in factor I that is associated with atypical hemolytic uremic syndrome does not affect the function of factor I in complement regulation. <i>Molecular Immunology</i> , 2007, 44, 1835-1844.	2.2	73

#	ARTICLE	IF	CITATIONS
199	Human neutrophil peptide-1 inhibits both the classical and the lectin pathway of complement activation. <i>Molecular Immunology</i> , 2007, 44, 3608-3614.	2.2	43
200	Regulation of Complement Activation by C-Reactive Protein: Targeting of the Inhibitory Activity of C4b-Binding Protein. <i>Journal of Immunology</i> , 2006, 176, 7612-7620.	0.8	98
201	Renal tubular epithelial cells modulate T-cell responses via ICOS-L and B7-H1. <i>Kidney International</i> , 2005, 68, 2091-2102.	5.2	44
202	Antibody Response Against the Glomerular Basement Membrane Protein Agrin in Patients with Transplant Glomerulopathy. <i>American Journal of Transplantation</i> , 2005, 5, 383-393.	4.7	125
203	C4b-binding protein binds to necrotic cells and DNA, limiting DNA release and inhibiting complement activation. <i>Journal of Experimental Medicine</i> , 2005, 201, 1937-1948.	8.5	92
204	A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. <i>British Journal of Rheumatology</i> , 2005, 44, 111-119.	2.3	54
205	Role of anti-C1q autoantibodies in the pathogenesis of lupus nephritis. <i>Expert Opinion on Biological Therapy</i> , 2005, 5, 243-251.	3.1	30
206	Activation of the lectin pathway in murine lupus nephritis. <i>Molecular Immunology</i> , 2005, 42, 731-740.	2.2	18
207	The C4b-binding Protein-Protein S Complex Inhibits the Phagocytosis of Apoptotic Cells. <i>Journal of Biological Chemistry</i> , 2004, 279, 23869-23873.	3.4	78
208	Anti-C1q autoantibodies in murine lupus nephritis. <i>Clinical and Experimental Immunology</i> , 2004, 135, 41-48.	2.6	38
209	Maturation of dendritic cells abrogates C1q production in vivo and in vitro. <i>Blood</i> , 2004, 103, 3813-3820.	1.4	157
210	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. <i>Journal of Clinical Investigation</i> , 2004, 114, 679-688.	8.2	185
211	Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. <i>Journal of Clinical Investigation</i> , 2004, 114, 679-688.	8.2	104
212	Glomerular deposition of C1q and anti-C1q antibodies in mice following injection of antimouse C1q antibodies. <i>Clinical and Experimental Immunology</i> , 2003, 132, 32-39.	2.6	59
213	Autoantibodies against mannose-binding lectin in systemic lupus erythematosus. <i>Clinical and Experimental Immunology</i> , 2003, 134, 335-343.	2.6	56
214	Immune deposition of C1q and anti-C1q antibodies in the kidney is dependent on the presence of glomerular IgG. <i>Molecular Immunology</i> , 2003, 40, 595-602.	2.2	23
215	Complement and renal disease. <i>Molecular Immunology</i> , 2003, 40, 125-134.	2.2	26
216	Diagnostic and prognostic significance of anti-C1q antibodies in systemic lupus erythematosus. <i>Current Opinion in Nephrology and Hypertension</i> , 2003, 12, 619-624.	2.0	83

#	ARTICLE	IF	CITATIONS
217	Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. <i>European Journal of Immunology</i> , 2002, 32, 1726.	2.9	276
218	Autoantibodies to complement components. <i>Molecular Immunology</i> , 2001, 38, 199-206.	2.2	39
219	Specific Inhibition of the Classical Complement Pathway by C1q-Binding Peptides. <i>Journal of Immunology</i> , 2001, 167, 7052-7059.	0.8	84